Advair Diskus is the brand name for fluticasone propionate and salmeterol, an inhaled corticosteroid and long-acting beta-agonist (ICS-LABA) combination made by GSK. The FDA approved Advair Diskus for twice-daily maintenance treatment of asthma in patients age 4 and older and for chronic obstructive pulmonary disease (COPD). The Diskus is a dry-powder inhaler delivered as a 30-day, 60-dose device in three strengths: 100/50, 250/50, and 500/50 mcg. Advair HFA is a separate aerosol version of the same combination.
Wixela Inhub, made by Viatris, received FDA approval on January 30, 2019 as the first generic version of Advair Diskus. Wixela Inhub uses the same fluticasone propionate and salmeterol formulation in the same three strengths and a comparable dry-powder inhaler device, and the FDA rated it therapeutically equivalent to brand Advair Diskus. Viatris priced Wixela Inhub's wholesale acquisition cost about 70 percent below brand Advair Diskus at launch, and that gap is still the main reason most patients switching off brand-name Advair Diskus in 2026 land on Wixela Inhub rather than an authorized generic.
GSK responded to inhaler-affordability pressure by announcing in 2024 that it would cap patient out-of-pocket cost at $35 per month across its entire respiratory portfolio, including Advair Diskus, Advair HFA, Breo Ellipta, and Trelegy Ellipta, for commercially insured and cash-paying patients. That cap continues into 2026. Separately, Advair Diskus was not among the drugs selected for Medicare price negotiation under the Inflation Reduction Act of 2022; the first ten negotiated drugs (Eliquis, Jardiance, Xarelto, and others) took effect January 1, 2026, and respiratory inhalers were not part of that round. Medicare Part D beneficiaries taking Advair Diskus instead rely on the general $2,100 annual out-of-pocket cap.
What Advair Diskus Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same advair diskus can cost many times more at a hospital than at your local pharmacy:
2026 Advair Diskus Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter, brand Advair Diskus (cash) | $350 - $600/month | List price without insurance for a 30-day, 60-dose Diskus |
| Pharmacy counter, generic Wixela Inhub (cash) | $64 - $105/month | FDA-approved generic since 2019; same strengths and dosing as brand |
| Medicare Part D (2026) | $10 - $75/month, capped at $2,100/year | Formulary tier and copay vary by plan; most plans do not require prior authorization for Advair Diskus itself |
| Commercial insurance with GSK savings card | $35/month or less | GSK's inhaler price cap applies to commercially insured and cash-paying patients only |
| Medicaid | $1 - $4/prescription | Covered as maintenance ICS-LABA therapy; some states require step therapy through generic Wixela Inhub first |
Retail and generic prices reflect 2026 pharmacy-chain survey data. Part D and Medicaid ranges depend on your specific plan's formulary tier and state.
Source: CMS Part D 2026 benefit design, GSK savings programs, pharmacy chain pricing surveys
Why Hospitals Charge So Much
Advair Diskus rarely appears on an inpatient hospital bill because it is a self-administered, twice-daily home inhaler rather than a drug infused or injected during a hospital stay. When it does show up on a facility bill, usually because a patient's home inhaler was logged as an administered medication during an asthma or COPD admission, the hospital pharmacy bills it at a facility rate that includes acquisition cost plus markups for pharmacy handling, nursing administration, and overhead.
Patients who see a single Advair Diskus dose billed at $200 or more on an itemized inpatient statement should request the line-item National Drug Code (NDC) and compare it to the 2026 wholesale acquisition cost of roughly $350 to $400 for a full 30-day Diskus. A per-dose or per-day charge that implies a monthly cost several times higher than that wholesale figure is a common target for a billing dispute or itemized-bill appeal, especially since Medicare and most commercial plans only reimburse the outpatient pharmacy rate.
Patient Assistance Programs
GSK, the manufacturer of Advair Diskus, and Viatris, the manufacturer of Wixela Inhub, both run programs that lower the cost far below the $350 to $600 cash retail price. If you are uninsured and cannot afford Advair Diskus at the counter, the GSK Patient Assistance Program can supply it free of charge; if you have commercial insurance, the manufacturer coupon path is usually faster and caps your cost at $35 per month.
Patient assistance programs for Advair Diskus| Manufacturer program | Cost / Benefit | How to apply |
|---|
| GSK Advair Diskus Savings Program | No more than $35 per month for commercially insured or cash-paying patients | gskforyou.com |
| GSK Patient Assistance Program (GSK Patient Access Programs Foundation) | Free Advair Diskus for uninsured or Medicare-only patients at or below 400% FPL | gskpaf.org |
| Wixela Inhub Savings Card (Viatris) | $10 per 30-day fill, up to $50 off, up to 12 fills per year for commercially insured patients | wixela.com/copay |
| NeedyMeds Drug Discount Card | Variable discount accepted at most US pharmacies for either product | needymeds.org |
Manufacturer savings cards from GSK and Viatris are not available to Medicare, Medicaid, TRICARE, or VA beneficiaries by federal anti-kickback law (42 U.S.C. section 1320a-7b). If you have government insurance, apply for the GSK Patient Assistance Program instead of trying to use a commercial manufacturer coupon.
Source: GSKforyou.com, GSK Patient Access Programs Foundation, Viatris Wixela Inhub savings program, NeedyMeds.org
Medicare Part D
Medicare Part D classifies both Advair Diskus and Wixela Inhub as covered respiratory drugs, though most Part D formularies place brand Advair Diskus on Tier 3 (non-preferred brand) and generic Wixela Inhub on Tier 1 or Tier 2 (generic or preferred). That tier difference is the main driver of your copay: Tier 3 copays commonly run $40 to $75 per month, while Tier 1 or Tier 2 copays for Wixela Inhub often run $10 to $30. Some plans require you to try Wixela Inhub before approving brand Advair Diskus through step therapy.
Your total out-of-pocket spending across all Part D drugs combined, brand and generic, is capped at $2,100 for 2026 under the Inflation Reduction Act of 2022. Once you hit that cap in a calendar year, you pay $0 for the rest of the year on covered drugs, including Advair Diskus or Wixela Inhub. Because Advair Diskus was not selected for IRA price negotiation, there is no separate Maximum Fair Price for it; the $2,100 general cap is the only federal cost ceiling that applies.
The Medicare Prescription Payment Plan, available since 2025, lets you spread your Part D out-of-pocket costs evenly across the calendar year instead of paying a large amount when you first fill Advair Diskus or Wixela Inhub. Ask your Part D plan to enroll you if a Tier 3 brand copay creates a high upfront bill early in the year.
Common Advair Diskus Billing Errors
If you got a bill for Advair Diskus above $75 with Medicare Part D, or above $35 with commercial insurance and a GSK savings card, check for these issues before paying:
- Brand Advair Diskus billed when your prescriber wrote for the generic, or vice versa. Wixela Inhub and brand Advair Diskus carry different NDCs and different formulary tiers, so a substitution error can double or triple your copay.
- Prior authorization or step-therapy paperwork never submitted for brand Advair Diskus, forcing you to pay the non-preferred Tier 3 cash rate when a Tier 1 or Tier 2 rate should have applied after generic substitution.
- One 60-dose Diskus billed as two separate 30-dose fills, doubling your copay. A single Advair Diskus device is a complete 30-day supply and should generate one copay per fill.
- Charged a deductible-phase rate after you already crossed the $2,100 Part D out-of-pocket cap for the calendar year.
- GSK's $35 manufacturer coupon or the Wixela Inhub Savings Card not applied at the register even though you are commercially insured and eligible. Ask the pharmacist to re-run the claim with the card's BIN/PCN.
Frequently Asked Questions
Is there a generic for Advair Diskus?
Yes. Wixela Inhub, made by Viatris, has been the FDA-approved generic version of Advair Diskus since January 30, 2019. It uses the identical fluticasone propionate and salmeterol formulation in the same three strengths and a comparable dry-powder inhaler device. GSK also sells its own authorized generic. Wixela Inhub typically costs $64 to $105 per month in 2026, roughly 70 to 85 percent less than brand Advair Diskus.
How do I apply for the GSK Patient Assistance Program?
Visit gskforyou.com or gskpaf.org, or call 1-888-825-5249, to request an application. Complete the patient section, have your prescriber sign the prescriber section, and submit proof of income, US residency, and insurance status (uninsured or Medicare only). GSK typically processes applications in 7 to 14 business days and ships approved medication directly to your home or prescriber's office at no cost. You must reapply annually.
Can I use the Advair Diskus savings card with Medicare?
No. Federal anti-kickback law bars manufacturer copay cards, including GSK's Advair Diskus Savings Program and the Wixela Inhub Savings Card, from being used by anyone with Medicare, Medicaid, TRICARE, or VA benefits. Those savings cards are for commercially insured or cash-paying patients only. If you have Medicare and cannot afford Advair Diskus, apply for the GSK Patient Assistance Program instead, which is open to Medicare beneficiaries who meet the income threshold.
What if my insurance denies coverage for Advair Diskus?
Request the written denial reason, then file a formal internal appeal with a letter of medical necessity from your prescriber, typically within 60 days for Medicare Part D. If the plan requires step therapy through generic Wixela Inhub first, ask your prescriber to document a prior failed trial or contraindication to request an override. If the appeal is denied twice, you can escalate to an independent external review. While the appeal is pending, the GSK Patient Assistance Program or savings card can keep your cost manageable.
Does the IRA negotiated price apply to Advair Diskus?
No. Advair Diskus was not among the first ten drugs selected for Medicare price negotiation under the Inflation Reduction Act of 2022; those negotiated Maximum Fair Prices, covering drugs like Eliquis and Jardiance, took effect January 1, 2026. Advair Diskus instead falls under the general 2026 Medicare Part D annual out-of-pocket cap of $2,100, which limits your total spending across all Part D drugs combined regardless of any single drug's negotiation status.
What does Advair Diskus cost without insurance at the pharmacy counter?
Brand Advair Diskus costs approximately $350 to $600 per 30-day, 60-dose Diskus in cash without insurance in 2026, depending on the pharmacy and strength. Switching to generic Wixela Inhub drops that to roughly $64 at CVS with a GoodRx coupon up to about $105 at Walmart for the same 30-day supply. GSK's manufacturer coupon can further reduce brand Advair Diskus to $35 per month for eligible cash-paying or commercially insured patients.
Do I qualify for the GSK Patient Assistance Program?
You generally qualify if your household income is at or below 400% of the federal poverty level in 2026, which is $63,840 for a household of one and $132,000 for a household of four, plus $22,720 for each additional person, and you are either uninsured or covered by Medicare only. You must also be a US resident with a valid Advair Diskus prescription. Patients with private commercial insurance do not qualify for the PAP and should use the manufacturer savings card instead.
What is the difference between Advair Diskus and Wixela Inhub?
Advair Diskus and Wixela Inhub both deliver the same active ingredients, fluticasone propionate and salmeterol, in the same three strengths through similar dry-powder inhaler devices, and the FDA rates them therapeutically equivalent. The main practical differences are manufacturer (GSK versus Viatris), the inhaler device's exact mechanism, and price: Wixela Inhub runs $64 to $105 per month in 2026 versus $350 to $600 for brand Advair Diskus. Most Medicare Part D and commercial plans place Wixela Inhub on a lower formulary tier.
